Mutation analysis of the WNT-4 gene in patients with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 22, Issue 9, 2006, Pages 484-487

  Canto, Patricia ^a   Söderlund, Daniela ^a   Carranza Lira, Sebastián ^b   Méndez, Juan Pablo ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Hospital Luis Castelazo Ayala   (Mexico)

Author keywords

Androgens; Mutations analysis; Polycystic ovary syndrome; Steroidogenic enzymes; WNT 4 gene

Indexed keywords

ANDROGEN; PROTEIN WNT 4; UNCLASSIFIED DRUG; WNT PROTEIN;

ALLELE; ANDROGEN SYNTHESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE REPRESSION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; INTRON; OPEN READING FRAME; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; FEMALE; HUMANS; MUTATION; POLYCYSTIC OVARY SYNDROME; PROTO-ONCOGENE PROTEINS; WNT PROTEINS;

EID: 33750481547     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600911698     Document Type: Article

References (32)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
3. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006;91:2-6.
4. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251-282.
5. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-353.
6. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-957.
7. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-419.
8. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998;329:209-223.
9. Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ. A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004;351:792-798.
10. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999;397:405-409.
11. Jeays-Ward K, Hoyle Ch, Brennan J, Dandonneau M, Alldus G, Capel B, Swain A. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 2003;130:3663-3670.
12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
13. Ferriman D, Gallwey J. Clinical assessment on body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1445.
14. Söderlund D, Canto P, Carranza-Lira S, Méndez JP. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod 2005;20:965-969.
15. Sambrook J, Russell D. Preparation and analysis of eukaryotic genomic DNA. In: Nolan C, editor. Molecular cloning: A laboratory manual. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001. pp 6.1-6.31.
16. Canto P, Razo E, Söderlund D, Calzada-León R, Ruíz-Reyes ML, Ramón G, Braun-Roth G, Méndez JP. Screening for mutations in the WNT-4 gene in patients with 46,XX true hermaphroditism. Mol Genet Metab 2004;83:341-343.
17. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
18. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-1876.
19. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
20. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
21. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS. Cellular mechanism of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:577-583.
22. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-111.
23. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-810.
24. Legro RS. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am 1999;28:379-396.
25. Treier M, Gleiberman AS, O'Connell SM, Szeto DP, McMahon JA, McMahon AP, Rosenfeld MG. Multistep signaling requirements for pituitary. Genes Dev 1998;12:1691-1704.
26. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA. Essential function of Wnt-4 inmammary gland development downstream of progesterone signaling. Genes Dev 2000;14:650-654.
27. Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 2002;143:4358-4365.
28. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994;372:679-683.
29. Jordan BK, Mohammed M, Ching ST, Délot E, Chen X-N, Dewing P, Swain A, Nagesh Rao P, Elejalde BR, Vilain E. Upregulation of Wnt-4 signalling and dosage-sensitive sex reversal in humans. Am J Hum Genet 2001;68:1102-1109.
30. Hsieh M, Johnson MA, Greenberg NM, Richards JS. Regulated expression of Wnts and Frizzleds at specific stages of follicular development in the rodent ovary. Endocrinology 2002;143:898-908.
31. Jeays-Ward K, Dandonneau M, Swain A. Wnt4 is required for proper male as well as female sexual development. Dev Biol 2004;276:431-440.
32. Heikkilä M, Prunskaite R, Naillat F, Itaranta P, Vuoristo J, Leppaluoto J, Peltoketo H, Vainio S. The partial female to male sex reversal in Wnt-4 deficient females involves induced expression of testosterone biosynthetic genes and testosterone production, and depends on androgen action. Endocrinology 2005;146:4016-4023.